12,000 koreans monitored for vaccine side effects over 6 years

NCT ID NCT05032976

Ongoing Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is monitoring the safety of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in 12,000 people in South Korea who received the vaccine as part of routine care. Researchers are tracking side effects like sore arms or fever within a week of each dose, as well as any other health issues that arise within a month. The goal is to gather real-world safety data from 2021 to 2027 to ensure the vaccine remains safe for the public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BNT162b2 (Pfizer-BioNTech COVID-19 vaccine)
What this could lead to: If successful, this study will provide real-world safety data on the BNT162b2 vaccine in a large Korean population, helping confirm its safety profile.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors and may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVERSE EFFECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVERSE EFFECTS COVID-19 SAFETY SARS-COV-2 VACCINES

Contacts and locations

Locations

Pfizer

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.